Immediate Graft Function (immediate + graft_function)

Distribution by Scientific Domains


Selected Abstracts


Robotic Transabdominal Kidney Transplantation in a Morbidly Obese Patient

AMERICAN JOURNAL OF TRANSPLANTATION, Issue 6 2010
P. Giulianotti
Kidney transplantation in morbidly obese patients can be technically demanding. Furthermore, morbidly obese patients experience a high rate of wound infections and related complications, which mostly result from the longer length and extent of the incision. These complications can be avoided through minimally invasive surgery; however, conventional laparoscopic instruments are unsuitable for the safe performance of a kidney transplant in morbidly obese patients. Herein, we report the first minimally invasive, total robotic kidney transplant in a morbidly obese patient. A left, deceased donor kidney was transplanted into a 29-year-old woman with a body mass index (BMI) of 41 kg/m2 who had been on hemodialysis for 5 years. The operation was performed intraabdominally using the DaVinci Robotic Surgical System with 4 trocars and a 7 cm midline incision. The operative time was 223 min, and the blood loss was less than 50 cc. The kidney had immediate graft function. No perioperative complications were observed, and the patient was discharged on postoperative day 5 with normal kidney function. Minimally invasive access and robotic technology facilitated the safe performance of a successful kidney transplant in a morbidly obese patient. [source]


Extreme Subcutaneous, Intramuscular and Inhaled Insulin Resistance Treated by Pancreas Transplantation Alone

AMERICAN JOURNAL OF TRANSPLANTATION, Issue 1 2010
J. R. Sa
Diabetes mellitus with resistance to insulin administered subcutaneously or intramuscularly (DRIASM) is a rare syndrome and is usually treated with continuous intravenous insulin infusion. We present here two cases of DRIASM in 16 and 18 years female patients that were submitted to pancreas transplantation alone (PTA). Both were diagnosed with type 1 diabetes as young children and had labile glycemic control with recurrent episodes of diabetic ketoacidosis. They had prolonged periods of hospitalization and complications related to their central venous access. Exocrine and endocrine drainages were in the bladder and systemic, respectively. Both presented immediate graft function. In patient 1, enteric conversion was necessary due to reflux pancreatitis. Patient 2 developed mild postoperative hyperglycemia in spite of having normal pancreas allograft biopsy and that was attributed to her immunosuppressive regimen. Patient 1 died 9 months after PTA from septic shock related to pneumonia. In 8 months of follow-up, Patient 2 presented optimal glycemic control without the use of antidiabetic agents. In conclusion, PTA may be an alternative treatment for DRIASM patients. [source]


The Transcriptome of the Implant Biopsy Identifies Donor Kidneys at Increased Risk of Delayed Graft Function

AMERICAN JOURNAL OF TRANSPLANTATION, Issue 1 2008
T. F. Mueller
Improved assessment of donor organ quality at time of transplantation would help in management of potentially usable organs. The transcriptome might correlate with risk of delayed graft function (DGF) better than conventional risk factors. Microarray results of 87 consecutive implantation biopsies taken postreperfusion in 42 deceased (DD) and 45 living (LD) donor kidneys were compared to clinical and histopathology-based scores. Unsupervised analysis separated the 87 kidneys into three groups: LD, DD1 and DD2. Kidneys in DD2 had a greater incidence of DGF (38.1 vs. 9.5%, p < 0.05) than those in DD1. Clinical and histopathological risk scores did not discriminate DD1 from DD2. A total of 1051 transcripts were differentially expressed between DD1 and DD2, but no transcripts separated DGF from immediate graft function (adjusted p < 0.01). Principal components analysis revealed a continuum from LD to DD1 to DD2, i.e. from best to poorest functioning kidneys. Within DD kidneys, the odds ratio for DGF was significantly increased with a transcriptome-based score and recipient age (p < 0.03) but not with clinical or histopathologic scores. The transcriptome reflects kidney quality and susceptibility to DGF better than available clinical and histopathological scoring systems. [source]


Dynamics of thromboxane level changes during early phase of allograft reperfusion

CLINICAL TRANSPLANTATION, Issue 5 2009
Barbara Do, gowska
Abstract:,Background:, Thromboxane (Tx) is a metabolite of arachidonic acid, which exerts a significant influence on kidney homeostasis, and may be involved in the pathogenesis of allograft rejection. The aim of this study was to: examine the dynamics of TxB2 changes during early phase of kidney allograft reperfusion, and analyze whether the observed changes in the concentrations and direction of TxB2 changes, are associated with post-transplant graft function. Methods:, Sixty-nine transplant recipients were divided into early, slow and delayed graft function group. Blood samples were collected directly before and during first the five minutes of allograft reperfusion. TxB2 concentrations were measured using ELISA. Creatinine and GFR levels were measured on the first, fifth, and 10th post-transplant day. Results:, The results demonstrated that during reperfusion significant differences in TxB2 concentrations occur in all groups. Moreover, significant differences in the concentrations, as well as in the dynamics of TxB2 changes between patients with immediate graft function, and individuals with allograft activation problems, were noticed. These differences were associated with post-transplant graft function. Conclusions:, Human renal transplantations are accompanied by changes in TxB2 concentrations, and the dynamics of TxB2 changes is associated with early post-transplant graft function. Our results also highlight TxB2 as a potential pre-transplant marker of post-transplant allograft function. [source]


Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

CLINICAL TRANSPLANTATION, Issue 6 2005
Silvio Sandrini
Abstract:, Delayed graft function (DGF) occurs in approximately 30% of renal transplant patients, and significantly increases risk of long-term graft loss. This article reviews the potential for use of interleukin-2 receptor (IL-2R) antagonists to reduce the burden of DGF. IL-2R antagonists decrease incidence of acute rejection without increasing risk of cytomegalovirus infection or malignancy, and show equivalent efficacy to lymphocyte-depleting antibody agents in standard risk patients with immediate graft function. The nephrotoxicity associated with calcineurin inhibitors (CNIs) has led to use of delayed or low-dose CNI regimens with induction therapy in patients with DGF. In this setting, use of an IL-2R antagonist with mycophenolate mofetil and steroids with delayed cyclosporine appears to be associated with a low incidence of biopsy-proven rejection and comparable renal function to patients with immediate function. Additionally, there is intriguing evidence to suggests that IL-2R antagonists may reduce risk of DGF occurring. A number of large-scale and smaller studies have reported a trend to reduced incidence of DGF or improved early renal function using IL-2R antagonists compared with placebo, although data are not entirely consistent. In conclusion, the ability of IL-2R antagonists to reduce acute rejection with no additional safety concerns makes them an attractive option for patients with DGF. [source]